Given the following risk assessment factors, what caries ris…
Questions
Given the fоllоwing risk аssessment fаctоrs, whаt caries risk is your 26 year old patient? Sealants on all first molars (# 3, #14, #19 & #30) at age 7 Sealants on lower second molars (#18 & #31) at age 12 Restoration of DO decay on #2 at age 14 Sealant on #15 at age 14 Uses fluoridated dentifrice daily Has one soda drink a day during 15 minute afternoon work break
Which sentence fоllоws оur best principles for mediа writing?
NEUROTRANSMITTERS (NTS) Bаsic Chаrаcteristics оf Neurоtransmitters Definitiоn Chemical signaling molecules synthesized by neurons to transmit information across synapses Storage Stored in presynaptic vesicles within axon terminals (classic NTs) Release Mechanism Action potential depolarizes presynaptic membrane Voltage-gated Ca²⁺ influx Vesicle fusion → exocytosis into synaptic cleft Post-synaptic Effects Binding to receptors: Ionotropic receptors (ligand-gated ion channels) Fast, direct ion flow → rapid response Metabotropic receptors (GPCRs) Second messenger systems → slower, amplified, longer-lasting effects Functional Outcomes Excitatory (EPSP) → depolarization Inhibitory (IPSP) → hyperpolarization Modulatory → alters neuronal excitability and synaptic strength Termination Requirement Rapid inactivation essential to prevent continuous stimulation Termination of Neurotransmitter Action Neurotransmitters are cleared via three main mechanisms: a) Reuptake Transport back into presynaptic neuron via specific transporter proteins Fates after reuptake: Repackaged into vesicles for reuse Enzymatic degradation inside neuron b) Diffusion NTs diffuse away from synaptic cleft into extracellular space or blood c) Enzymatic Degradation (Synaptic Cleft) Breakdown by specific enzymes in extracellular space Rapid termination of signal Drug Targets in Neurotransmitter Pathways Pharmacologic agents may alter NT signaling at multiple steps: Synthesis inhibition or enhancement Storage disruption (vesicular transport interference) Release modulation ↑ or ↓ vesicle exocytosis Reuptake blockade Prolongs synaptic NT activity Enzyme inhibition Prevents NT degradation Receptor modulation Agonists / antagonists Signal transduction alteration Affects intracellular second messenger pathways Classification of Neurotransmitters A. Classical (Canonical) Neurotransmitters Synthesized primarily in neuronal cytoplasm Exception: norepinephrine partially synthesized in vesicles Acetylcholine (ACh) Ester-type neurotransmitter Monoamines (Biogenic amines) Catecholamines (from tyrosine) Dopamine (DA) Norepinephrine (NE) Epinephrine (E) Other monoamines Histamine (from histidine) Serotonin (5-HT, from tryptophan) Amino Acid Neurotransmitters Excitatory Glutamate (primary excitatory CNS NT) L-aspartate Inhibitory GABA (major inhibitory CNS NT) Glycine (spinal cord inhibitory NT) Modulatory amino acid: D-serine (NMDA receptor co-agonist) B. Non-Classical (Non-Canonical) Neurotransmitters Not stored in classic synaptic vesicles Can act in retrograde signaling (postsynaptic → presynaptic) Often diffuse or act intracellularly Neuropeptides Substance P Neuropeptide Y Somatostatin Endogenous opioids (endorphins, enkephalins) Vasoactive intestinal peptide (VIP) Endocannabinoids Retrograde signaling molecules Lipid-derived mediators Gasotransmitters Nitric oxide (NO) Diffuses freely across membranes Acts intracellularly (e.g., cyclic GMP pathways) Purinergic Neurotransmitters ATP Adenosine Appetite-Regulating Peptides Orexin Ghrelin Termination of Specific Neurotransmitters Acetylcholine (ACh) Rapid degradation in synaptic cleft by acetylcholinesterase (AChE) ACh → choline + acetate Choline is: Reuptaken into presynaptic neuron Recycled for ACh synthesis AChE Types True AChE (Cholinesterase I) Located in synapses and erythrocytes (RBCs) Pseudocholinesterase (Butyrylcholinesterase; ChE II / BCHE) Found in plasma and liver Broader substrate specificity (e.g., butyrylcholine) Dopamine (DA) Precursor to NE and E Termination pathways Reuptake via dopamine transporter (DAT) Repackaged into vesicles OR Degraded enzymatically Enzymatic degradation: Monoamine oxidase (MAO) Catechol-O-methyltransferase (COMT) Extraneuronal metabolism: Occurs in synaptic space via MAO & COMT Diffusion: Into surrounding tissues or circulation Norepinephrine (NE) & Epinephrine (E) Termination pathways Reuptake via norepinephrine transporter (NET) Repackaging into vesicles OR Enzymatic degradation Enzymes involved: MAO (intraneuronal) COMT (extraneuronal/synaptic space) Additional fate: Diffusion into tissues or bloodstream Question: A 62-year-old patient is found to have prolonged parasympathetic effects after exposure to a cholinergic agent, and symptoms improve after administration of a drug that inhibits acetylcholinesterase, which neurotransmitter termination mechanism is primarily being affected?
VOLUME OF DISTRIBUTION (Vd) Definitiоn Vd = аppаrent vоlume in which tоtаl drug amount would need to be uniformly distributed to achieve the same concentration as in plasma Reflects extent of drug distribution into tissues vs staying in plasma Formula: Vd = Amount of drug in body / Plasma drug concentration Core Interpretation Low Vd → drug remains mainly in plasma/blood compartment Example pattern: large, hydrophilic, highly protein-bound drugs High Vd → extensive tissue distribution (interstitial + intracellular compartments) Suggests lipid solubility or strong tissue binding Determinants of Vd Blood flow ↑ Blood flow → ↑ tissue delivery → ↑ Vd Highly perfused organs receive drug first (brain, liver, heart) Capillary permeability ↑ Permeability → easier tissue entry → ↑ Vd BBB restricts hydrophilic drugs → lowers Vd Drug physicochemical properties Molecular weight: ↑ MW → ↓ Vd (poor tissue diffusion) Lipid solubility: ↑ lipophilicity → ↑ Vd (membrane penetration) Ionization: ↑ ionized form → ↓ Vd (poor membrane crossing) Plasma protein binding (PPB) Main protein: Albumin Only free (unbound) drug is active, distributed, and cleared ↑ PPB → ↓ free drug → ↓ tissue diffusion → ↓ Vd Also acts as drug reservoir → prolongs duration & delays elimination Highly bound drugs (high clinical relevance): Warfarin, phenytoin Key clinical implications: Small PPB changes → large ↑ free drug → toxicity risk Liver disease → ↓ albumin → ↑ free drug effect/toxicity Drug–drug competition → displacement → sudden ↑ active drug fraction Tissue binding Drugs may accumulate in tissues (reversible or poorly reversible binding) Effect: ↑ Vd Prolonged action Delayed elimination Toxicity examples: Tetracyclines → bone/teeth → growth defects Aminoglycosides → kidney & inner ear → nephrotoxicity, ototoxicity Redistribution Drug moves from highly perfused organs → muscle/fat over time Leads to: Rapid onset (brain exposure) Rapid termination (fall in brain concentration despite drug still in body) Classic example: Highly lipid-soluble IV anesthetics (e.g., ultra-short barbiturates) → brief effect due to redistribution Question: A 58-year-old man with cirrhosis is started on warfarin therapy and is found to have hypoalbuminemia compared with baseline; what is the most likely effect?